Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Comparison of the efficacy, safety and tolerability of policosanol versus fluvastatin in elderly hypercholesterolaemic women
Autore:
Fernandez, JC; Mas, R; Catano, G; Menendez, R; Amor, AM; Gonzalez, RM; Alvarez, E;
Indirizzi:
Natl Ctr Sci Res, Ctr Nat Prod, Havana 6880, Cuba Natl Ctr Sci Res Havana Cuba 6880 i Res, Ctr Nat Prod, Havana 6880, Cuba Med Surg Res Ctr, Havana, Cuba Med Surg Res Ctr Havana CubaMed Surg Res Ctr, Havana, Cuba
Titolo Testata:
CLINICAL DRUG INVESTIGATION
fascicolo: 2, volume: 21, anno: 2001,
pagine: 103 - 113
SICI:
1173-2563(2001)21:2<103:COTESA>2.0.ZU;2-4
Fonte:
ISI
Lingua:
ENG
Soggetto:
LOW-DENSITY-LIPOPROTEIN; COA REDUCTASE INHIBITOR; II HYPERCHOLESTEROLEMIA; CORONARY RISK; LIPID-PEROXIDATION; CHOLESTEROL LEVELS; SUSCEPTIBILITY; PRAVASTATIN; PROFILE; THERAPY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
58
Recensione:
Indirizzi per estratti:
Indirizzo: Mas, R Natl Ctr Sci Res, Ctr Nat Prod, POB 6990, Havana 6880, Cuba Natl Ctr Sci Res POB 6990 Havana Cuba 6880 6990, Havana 6880, Cuba
Citazione:
J.C. Fernandez et al., "Comparison of the efficacy, safety and tolerability of policosanol versus fluvastatin in elderly hypercholesterolaemic women", CLIN DRUG I, 21(2), 2001, pp. 103-113

Abstract

Objective: To compare the efficacy and tolerability of policosanol with that of fluvastatin in older hypercholesterolaemic women. Design and Setting: Randomised, single-blind, parallel-group study performed at a single centre in Cuba. Patients and Participants: 70 women aged 60 to 80 years with type II hypercholesterolaemia. Methods: Patients were randomised after 4 weeks' dietary stabilisation on a step-one cholesterol-lowering diet to treatment with policosanol (10mg) or fluvastatin (20mg) tablets once daily for 8 weeks. Results: Policosanol significantly lowered low density lipoprotein cholesterol (LDL-C) [29.2%, p < 0.001], total cholesterol (TC) [19.3%, p <0.001], triglycerides (7%, p < 0.05) and the ratios of LDL-C (39.8%, p < 0.001) andTC (31.6%, p < 0.001) to high density lipoprotein cholesterol (HDL-C), andsignificantly increased HDL-C (19.8%, p < 0.001). Fluvastatin significantly lowered LDL-C (22.9%, p < 0.001), TC (16.7%, p < 0.001), triglycerides (8.2%, p < 0.05), LDL-C/HDL-C (28.4%, p < 0.001) and TC/HDL-C (22.8%, p < 0.001), and significantly increased HDL-C (9.2%, p < 0.001). Policosanol was more effective than fluvastatin in reducing LDL-C (p < 0.01), TC/HDL-C (p < 0.01) and LDLC/HDL-C (p < 0.001) as well as in increasing HDL-C (p < 0.01). Policosanol, but not fluvastatin, significantly increased lag time for LDLlipid peroxidation (36.5%, p < 0.001) and significantly decreased the diene peroxidation rate (15.5%, p < 0.05). Both treatments were well tolerated. Five fluvastatin, but no policosanol, recipients discontinued the study, three because of adverse events (chest pain and gastric discomfort, skin rash, and dizziness). Overall, three policosanol and five fluvastatin recipients reported adverse events during the study. Conclusions: The cholesterol-lowering effects of policosanol 10 mg/day administered for 8 weeks to older women with type II hypercholesterolaemia were slightly better than those of fluvastatin 20 mg/day with respect to the extent of the changes in LDL-C, atherogenic indices and HDL-C levels. In addition, policosanol, but not fluvastatin, significantly inhibited the susceptibility of LDL to undergo lipid peroxidation in this particular study population, Nevertheless, further studies in larger populations and with higherdosages must be conducted to corroborate the present results.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/04/20 alle ore 01:23:34